12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Haemocomplettan P human fibrinogen concentrate: Phase II data

Researchers at CSL and Hannover Medical School reported data from a double-blind, German Phase II trial in 61 patients undergoing elective aortic replacement surgery with cardiopulmonary bypass showing that patients receiving Haemocomplettan P when clinically relevant bleeding occurred required significantly fewer units of allogeneic blood components between the time of treatment and 24 hours thereafter, the primary endpoint, vs. placebo...

Read the full 289 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >